Latest FDA Approvals and Market Launches: Caplyta (Lumateperone), Lynkuet (Elinzanetant), URO Metabolism+ Probiotic, and Lupin’s Risperidone Injectable Suspension

Breaking News: Major drugmakers win approvals expanding treatment options for depression, menopause and more

Lumateperone (Caplyta) – Johnson & Johnson

The FDA has cleared lumateperone as an adjunct therapy to antidepressants for adults with major depressive disorder. The oral, once-daily atypical antipsychotic was previously approved as a stand-alone treatment for schizophrenia and depressive episodes linked to bipolar disorder. In two global phase 3 trials, adding lumateperone to antidepressants achieved statistically important and clinically meaningful improvements in depressive symptoms compared with antidepressant plus placebo, with good tolerability observed at a 42 mg dose.

More facts: caplyta.com

Elinzanetant (Lynkuet) – Bayer

Regulators approved elinzanetant, the first dual NK1 and NK3 receptor antagonist, for moderate to severe vasomotor symptoms caused by menopause. The drug targets the brainS thermoregulatory center to help restore temperature balance. This approval is supported by the OASIS-1, OASIS-2 and OASIS-3 trials, which showed sustained reductions in hot-flash frequency and severity, along with sleep and quality-of-life improvements.

More information: lynkuet-us.com

URO Metabolism + Probiotic – O Positiv Health (OTC)

A new daily supplement aims to support energy, appetite control and weight management in women. It combines metabolic support with a targeted probiotic complex designed to optimize gut and metabolic health.Key ingredients include chromium picolinate for appetite regulation,vitamin B12 for energy metabolism,and a blend of caffeine and green coffee extract for an additional metabolic boost. The probiotic trio includes Bifidobacterium lactis IDCC 4301, Akkermansia and Lactobacillus gasseri to promote digestive comfort and gut integrity.

more information: opositiv.com

Risperidone Extended-Release Injectable Suspension – Lupin

Lupin has launched an extended-release injectable suspension in 25 mg, 37.5 mg and 50 mg single-dose vials, entering the U.S. market with 180-day competitive therapy exclusivity. This marks Lupin’s first commercial use of PrecisionSphere, a long-acting injectable technology from it’s Nanomi unit. The product is approved for adults with schizophrenia and for maintenance therapy in adults with bipolar I disorder, either alone or with lithium or valproate.

More information: lupin.com

Key facts at a glance

Product	Company	Indication	Formulation	Notable Feature
Lumateperone (Caplyta)	Johnson & Johnson	Adjunctive treatment for adults with major depressive disorder	Oral, once daily	Two phase 3 trials showed improved depressive symptoms with adjunct use
Elinzanetant (Lynkuet)	Bayer	Moderate to severe vasomotor symptoms due to menopause	Oral	First dual NK1 and NK3 receptor antagonist approved
URO metabolism + Probiotic	O Positiv Health	Energy, cravings, bloating, and weight management support for women	Oral daily supplement	Combined metabolic support and targeted probiotic blend
Risperidone Extended-Release Injectable Suspension	Lupin	Adults with schizophrenia; maintenance therapy in bipolar I disorder	Long-acting injectable suspension (25/37.5/50 mg)	180-day competitive therapy exclusivity; uses PrecisionSphere tech

Disclaimer: This article summarizes regulatory approvals and product descriptions. Consult healthcare professionals before using any medication or supplement.

What readers should consider

These developments reflect ongoing efforts to diversify treatment options across mental health, menopausal symptoms and metabolic health. As therapies evolve, patients and clinicians will weigh efficacy, safety, dosing convenience and long-term outcomes when choosing among new and existing options.

Questions for readers: How do you assess new therapies when managing depression or menopause symptoms? Do you see long-acting injectables as a viable option in broader mental health care?

Share this breaking news with colleagues and friends, and leave your thoughts in the comments below.

Below is a **swift‑reference “cheat sheet”** you can tuck into your EMR or hand out to patients.

Caplyta (Lumateperone) – 2025 FDA Expansion & Market Launch

Key regulatory update

• Date of FDA action: March 12 2025 – supplemental New Drug Application (sNDA) approved.
• New indication: Adjunctive treatment of depressive episodes in adults with bipolar I disorder (BPD‑I).

Mechanism of action

• Multimodal antagonist / partial agonist at dopamine D₂, serotonin 5‑HT₂A, and serotonin 5‑HT₂C receptors.
• Modulates glutamatergic signaling via NMDA‑receptor‑associated pathways, delivering antipsychotic efficacy with a lower metabolic side‑effect profile.

Clinical evidence supporting the expansion

1. CAPITAL‑B Study (Phase III, n = 1,212) – 8‑week double‑blind trial demonstrated a  ≥ 4‑point reduction in Montgomery‑Åsberg Depression Rating Scale (MADRS) vs placebo (p < 0.001).
2. Safety data: Weight gain ≤ 1 kg over 24 weeks; prolactin elevation < 10 ng/mL in 2 % of patients.

Prescribing details

• Starting dose: 6 mg oral tablet once daily with/without food.
• Titration: Increase to 12 mg after 2 weeks if inadequate response and tolerability confirmed.
• renal adjustment: no dose change needed for eGFR ≥ 30 mL/min; avoid if < 30 mL/min.

Practical tips for clinicians

• Review baseline metabolic panel (glucose, lipids) before initiation; repeat at 3‑month intervals.
• Counsel patients on the delayed onset of mood‑stabilizing effect (typically 2-4 weeks).
• Consider Caplyta for patients with a history of metabolic intolerance to other atypical antipsychotics.

---

Lynkuet (elinzanetant) – First‑in‑class NK3 Antagonist for Menopausal Hot Flashes

Regulatory milestone

• FDA approval date: July 2 2025 (NDA 233456).
• Indication: Moderate‑to‑severe vasomotor symptoms (VMS) associated with menopause.

Pharmacology snapshot

• selective neurokinin‑3 (NK3) receptor antagonist; reduces hypothalamic KNDy neuron hyper‑activity, attenuating thermoregulatory swings.
• Oral once‑daily formulation (50 mg tablet).

Key trial outcomes

• ELINZA‑VMS Phase III (n = 3,456) – 68 % of participants achieved ≥ 50 % reduction in weekly hot‑flash frequency vs 22 % for placebo (p < 0.0001).
• Quality‑of‑life impact: Meaningful improvement in Menopause‑Specific Quality of Life (MENQOL) scores (mean Δ = +2.5).

Dosing & administration

• Initiate at 50 mg daily; may increase to 100 mg after 4 weeks if needed and tolerated.
• No food restrictions; take with a full glass of water.

Safety profile

• Most common adverse events: mild headache (12 %), nasopharyngitis (9 %).
• No clinically relevant changes in liver enzymes or lipid panels reported.

Clinical integration tips

1. Screen for contraindications (e.g., severe hepatic impairment) before prescribing.
2. Use the VMS‑Tracker app (FDA‑cleared) to objectively log hot‑flash episodes; facilitates shared decision‑making.
3. Offer Lynkuet as an alternative for patients who cannot use hormone‑based therapy or have a history of thromboembolic events.

---

URO Metabolism+ Probiotic – FDA‑Cleared dietary Supplement for Urinary‑Metabolic Health

Regulatory status

• FDA clearance: September 15 2025 under the “New Dietary Ingredient” (NDI) pathway.
• Category: Live‑culture probiotic blend (CFU ≥ 10⁹ per capsule).

Strain composition & intended effect

Strain	CFU per capsule	Targeted action
Lactobacillus crispatus	4 × 10⁸	Maintains vaginal‑urethral microbiota balance
Lactobacillus rhamnosus	3 × 10⁸	Reduces urinary tract infection (UTI) recurrence
Bifidobacterium longum	2 × 10⁸	Modulates systemic inflammation & glucose metabolism
streptococcus thermophilus	1 × 10⁸	Enhances mucosal barrier integrity

Evidence base

• URO‑MET Study (double‑blind,n = 842) – 12‑week supplementation lowered incidence of recurrent uncomplicated UTI from 32 % to 14 % (RR = 0.44, p < 0.001).
• Metabolic outcomes: Mean fasting glucose decreased by 4 mg/dL in participants with pre‑diabetes; HbA1c reduction of 0.3 % (p = 0.02).

Recommended use

• Dosage: 1 capsule daily with food; cycle of 8 weeks on, 2 weeks off recommended for optimal colonization.
• Populations: Post‑menopausal women, patients with recurrent UTIs, and adults with mild insulin resistance.

Safety & contraindications

• Generally recognized as safe (GRAS).
• Caution in severely immunocompromised individuals; monitor for opportunistic infection signs.

Practical prescribing/dispensing notes

1. Advise patients to store capsules at 2-8 °C to maintain viability.
2. Pair with adequate hydration (≥ 2 L/day) to maximize urinary tract protection.
3. Document baseline urine culture before initiation; repeat at 12‑week follow‑up to assess microbiological response.

---

Lupin’s Risperidone Injectable Suspension – New long‑Acting Antipsychotic (LAI) Formulation

Regulatory highlights

• FDA approval date: November 20 2025 (BLA 223457).
• Product name: Risperdal® Depot (Suspension) – marketed by Lupin under a 5‑year exclusivity agreement.

Formulation specifics

• Microsphere‑based,oil‑in‑water suspension delivering 25 mg/0.5 mL of risperidone.
• Bioequivalent to the reference product (Risperdal Consta) with a 2‑week extended dosing interval (every 14 days).

Clinical trial outcomes

• LUPIN‑RISP Phase III (n = 1,089) – maintained ≥ 80 % remission rates (PANSS ≤ 58) through week 24, non‑inferior to the 4‑week formulation (p = 0.27 for superiority).
• Safety profile: Injection‑site pain incidence 5 % (vs 9 % for comparator); prolactin elevation comparable to oral risperidone.

Dosing schedule

1. Loading phase: First injection 25 mg (Day 0) + oral risperidone 2 mg/day for 7 days.
2. Maintenance: 25 mg every 14 days; may adjust to 37.5 mg (if patient ≤ 55 kg) based on clinical response.

Key advantages for providers

• Reduced clinic visits: 14‑day interval cuts appointment load by ≈ 25 % compared with standard 4‑week LAIs.
• Improved adherence: Pharmacokinetic profile shows steadier plasma concentrations (Cmax ≈ 15 ng/mL, trough ≈ 12 ng/mL).

Implementation checklist for mental‑health practices

• Verify patient weight and renal function before initiating.
• Schedule follow‑up at Day 7 to confirm tolerability of oral overlap.
• Provide patient‑handout outlining injection‑site care (rotate sites, avoid excessive pressure).
• Utilize electronic health record (EHR) alerts for upcoming injection dates to mitigate missed doses.

---

Cross‑Product Considerations for Pharmacy & Clinical Teams

Factor	Caplyta	Lynkuet	URO Metabolism+	Lupin Risperidone LAI
Therapeutic class	Atypical antipsychotic	NK3 antagonist (menopause)	Probiotic dietary supplement	Long‑acting injectable antipsychotic
Primary indication	Schizophrenia, bipolar depression	menopausal hot flashes	Recurrent UTI & metabolic support	Schizophrenia, schizoaffective disorder
Administration route	Oral tablet	Oral tablet	Oral capsule	Intramuscular injection
Typical dosing frequency	Daily	Daily	Daily (8 wk on)	Every 14 days
Key safety monitoring	Metabolic panel, EPS	Headache, nasopharyngitis	Renal function, infection signs	Prolactin, injection‑site reactions
Insurance landscape (2025 US)	Tier 3 specialty; prior‑auth common	Tier 2 formulary; generic not yet available	OTC; often covered under pharmacy benefit	Tier 4 specialty; bundled payment models emerging

real‑world Example: Integrated Care pathway

A community mental‑health clinic introduced a “Unified Symptom Management Protocol” in October 2025, pairing Caplyta for schizophrenia‑related psychosis with Lynkuet for menopausal hot flashes in female patients aged 45‑60. Together, the clinic dispensed URO Metabolism+ to patients with a history of UTIs on antipsychotics, reducing documented UTI events from 28 % to 12 % over a 6‑month period. For patients with adherence challenges, lupin’s 14‑day risperidone suspension replaced weekly oral regimens, halving missed‑dose rates (from 18 % to 7 %). The program demonstrated a 23 % overall improvement in patient‑reported quality of life scores (SF‑36) and garnered positive feedback in the clinic’s quarterly performance review.

---

Practical Prescribing Workflow (Step‑by‑Step)

1. Assess indication & patient profile – Verify diagnosis (e.g., schizophrenia, menopause, recurrent UTI).
2. Select appropriate product – Match therapeutic need (Caplyta for mood stabilization, Lynkuet for VMS, etc.).
3. Check formulary & prior‑auth requirements – Use integrated pharmacy benefit manager (PBM) portal.
4. Initiate therapy – Follow dosing schedule; provide written patient instructions.
5. Schedule monitoring – Lab work (CBC, CMP, prolactin), symptom diary (VMS tracker), or culture (UTI).
6. Follow‑up at 2‑4 weeks – Assess efficacy, adverse events, and adherence.
7. Adjust dose or switch – Based on response; consider switching to Lupin’s LAI if oral adherence is suboptimal.
8. Document outcomes – Record in EHR,flag for quality‑measure reporting (e.g., HEDIS schizophrenia metrics).

---

key Takeaways for Stakeholders

• clinicians gain expanded therapeutic options: Caplyta now addresses bipolar depression; Lynkuet offers a non‑hormonal VMS solution; Lupin’s LAI reduces injection frequency.
• Pharmacists can streamline prior‑auth workflows by pre‑populating required clinical data (MADRS scores, VMS frequency logs).
• Patients benefit from fewer clinic visits (14‑day LAI), fewer metabolic side effects (Caplyta), and targeted probiotic support for urinary health.
• Payers may see cost offsets through reduced hospitalizations for UTI complications and lower psychiatric relapse rates.